Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016321 · ClinicalTrials.gov registry record · Phase 2
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
A Phase 2 study, sponsored by Johns Hopkins University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT07016321: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT07016321 is a Phase 2 study that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07016321, a Phase 2 study, has not yet begun recruiting, sponsored by Johns Hopkins University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.
Interventions
- DRUG Placebo
- DRUG Emetine Hydrochloride 6mg
- DRUG Emetine Hydrochloride 12mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-06-25 |
| Est. Completion | 2029-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016321
The ClinicalTrials.gov registry entry for NCT07016321 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07016321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07016321 about?
NCT07016321 is a clinical study titled "Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)". The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma lea...
What is the current status of trial NCT07016321?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2026-06-25. Estimated completion is 2029-05-03.
What interventions are being tested in trial NCT07016321?
The interventions under investigation include: Placebo (DRUG), Emetine Hydrochloride 6mg (DRUG), Emetine Hydrochloride 12mg (DRUG).
Who is sponsoring clinical trial NCT07016321?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.